OX40-OX40L interactions: A promising therapeutic target for allergic diseases?

Journal of Clinical Investigation

Volumn 117, Issue 12, 2007, Pages 3655-3657

  Wang, Yui Hsi ^a   Liu, Yong Jun ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN;

ALLERGIC DISEASE; CD4+ T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TH2 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; CRICETINAE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; INFLAMMATION; LUNG; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; OX40 LIGAND; RECEPTORS, OX40; SKIN; TH2 CELLS; TUMOR NECROSIS FACTORS;

EID: 36849046819     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34182     Document Type: Review

References (25)

1. Kay, A.B. 2001. Allergy and allergic diseases. Second of two parts. N. Engl. J. Med. 344:109-113.
2. Holgate, S.T. 2007. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol. 28:248-251.
3. Soumelis, V., et al. 2002. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat. Immunol. 3:673-680.
4. Ying, S., et al. 2005. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol. 174:8183-8190.
5. Liu, Y.J. 2006. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203:269-273.
6. Ito, T., et al. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213-1223.
7. Wang, Y.H., et al. 2006. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity. 24:827-838.
8. Yoo, J., et al. 2005. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med. 202:541-549.
9. Al Shami, A., Spolski, R., Kelly, J., Keane-Myers, A., and Leonard, W.J. 2005. A role for TSLP in the development of inflammation in an asthma model. J. Exp. Med. 202:829-839.
10. Zhou, B., et al. 2005. Thymic stromal lymphopoietin as a key initiator of allergic airway inflammation in mice. Nat. Immunol. 6:1047-1053.
11. Allakhverdi, Z., et al. 2007. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med. 204:253-258.
12. Paterson, D.J., et al. 1987. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol. Immunol. 24:1281-1290.
13. Godfrey, W.R., Fagnoni, F.F., Harara, M.A., Buck, D., and Engleman, E.G. 1994. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J. Exp. Med. 180:757-762.
14. Ohshima, Y., et al. 1998. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood. 92:3338-3345.
15. Chen, A.I., et al. 1999. Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity. 11:689-698.
16. Sugamura, K., Ishii, N., and Weinberg, A.D. 2004. Therapeutic targeting of the effector T-cell costimulatory molecule OX40. Nat. Rev. Immunol. 4:420-431.
17. Wang, Y.H., et al. 2007. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J. Exp. Med. 204:1837-1847.
18. Hoshino, A., et al. 2003. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur. J. Immunol. 33:861-869.
19. Salek-Ardakani, S., et al. 2003. OX40 (CD134) controls memory T helper 2 cells that drive lung inflammation. J. Exp. Med. 198:315-324.
20. Seshasayee, D., et al. 2007. In vivo blockade of OX40 ligand inhibits thymic stromal lymphopoietin driven atopic inflammation. J. Clin. Invest. 117:3868-3878.
21. Weinberg, A.D., et al. 1996. Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat. Med. 2:183-189.
22. Weinberg, A.D., Wegmann, K.W., Funatake, C., and Whitham, R.H. 1999. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 162:1818-1826.
23. Arestides, R.S., et al. 2002. Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation. Eur. J. Immunol. 32:2874-2880.
24. Li, M., et al. 2005. Retinoid X receptor ablation in adult mouse keratinocytes generates an atopic dermatitis triggered by thymic stromal lymphopoietin. Proc. Natl. Acad. Sci. U.S.A 102:14795-14800.
25. Liu, Y.J. 2007. Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation. J. Allergy Clin. Immunol. 120:238-244.